12:00 AM
 | 
Oct 07, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sativex regulatory update

GW Pharmaceuticals' European marketing partner Almirall S.A. (Madrid:ALM, Barcelona, Spain) renegotiated the reimbursement price in Germany for Sativex to treat spasticity due to multiple sclerosis with Germany's Statutory Health Insurance Funds Association (GKV-Spitzenverband). GW said it is "pleased" with the price, which is an undisclosed premium to the...

Read the full 226 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >